-
CSPC Pharmaceutical’s Narlumosbart Approved by NMPA for Bone Giant Cell Tumors
•
CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, Shanghai JMT Biotechnology Co., Ltd, has received marketing approval from the National Medical Products Administration (NMPA) for narlumosbart (JMT103), an anti-RANKL monoclonal antibody (mAb), to treat giant cell tumors of bone that are inoperable or may lead to severe…
-
CSPC Pharmaceutical’s JMT103 Anti-RANKL Antibody Prioritized for CDE Review
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its market filing for JMT103, an anti-RANKL monoclonal antibody (mAb) developed by subsidiary Shanghai JMT Biotechnology Co., Ltd, has been prioritized for review by the Center for Drug Evaluation (CDE). The drug is designed to address deficiencies in existing RANKL antibodies,…
-
CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies
•
The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) subsidiary Shanghai JMT Biotechnology Co., Ltd for its anti-RANKL monoclonal antibody (mAb) JMT103 has been accepted for review. This next-generation RANKL antibody aims to address the shortcomings of existing marketed…
